1. In Vivo
  2. >>Outlook

Neoadjuvant Cancer Immunotherapy Set For Takeoff, Fueled By Strong Data

 
• By Emily Hayes

Dreams of a future with early curative treatments drives wave of drug development in pre-surgical and perioperative treatment in many tumor types.

Neoadjuvant use of IO therapy is set for launch

Neoadjuvant cancer immunotherapy is poised to advance in 2025 and beyond, giving hope that in the future patients could be cured early, perhaps escaping debilitating surgeries. For biopharma companies, the race is on to efficiently detect early signals of efficacy and develop safe and effective regimens suitable for pre-surgical use.

Drug developers and academic researchers are exploring neoadjuvant (pre-surgical) treatment alone as well as perioperative approaches, which combine neoadjuvant with adjuvant (post-surgical) treatment. Overall, development of neoadjuvant and perioperative cancer immunotherapies is very active, data from Biomedtracker show 35 ongoing clinical trials over 16 indications

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Outlook

More from Innovation

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By Ian Taylor

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.